Literature DB >> 8895923

Cytomegalovirus in peripheral blood leukocytes of infants with congenital or postnatal infection.

M Barbi1, S Binda, V Primache, C Novelli.   

Abstract

BACKGROUND: Cytomegalovirus (CMV) is the most frequent agent of viral infection in the fetus; it causes varying damage, particularly neurologic, which becomes evident at birth or in infancy in about 20% of infected individuals. Postnatal acquisition is usually asymptomatic and without sequelae. Laboratory diagnosis of congenital and postnatal infection is based on the demonstration of virus in urine.
OBJECTIVES: To investigate the systemic spread of CMV in neonates with congenital or postnatal infection and to evaluate its significance in diagnosis and in monitoring anti-CMV treatments.
DESIGN: Quantitative determinations of infective CMV (viremia) and viral antigen pp65 (antigenemia) were performed on peripheral blood leukocytes (PBL) from the buffy coat of heparinized blood from children with a diagnosis of congenital (n = 19) or postnatal (n = 19) infection based on viral isolation from urine.
RESULTS: Antigen pp65 in PBL was detected particularly in children with symptomatic infection, both congenital (100%) and postnatal (79%; P > 0.05), and significantly less frequently (50%; P < 0.001) in those with asymptomatic infection. Viremia was observed less often but always in association with antigenemia. Both tests became negative within 6 months. Neither viral titer nor persistent positivity was related to clinical manifestations. In the nine infants given anti-CMV therapy (ganciclovir and/or hyperimmune gamma-globulins) an early suspension of treatment resulted in the appearance of antigenemia and/or viremia.
CONCLUSIONS: Cytomegalovirus was detected in PBL mainly in the most severely affected children. Monitoring antigenemia and viremia in CMV-infected infants is recommended to demonstrate persistent systemic infection and to evaluate virologic results of treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8895923     DOI: 10.1097/00006454-199610000-00013

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  7 in total

Review 1.  Safety of alternative antiviral agents for neonatal herpes simplex virus encephalitis and disseminated infection.

Authors:  Yu Wang; Katherine P Smith
Journal:  J Pediatr Pharmacol Ther       Date:  2014-04

2.  Congenital cytomegalovirus infection - An update.

Authors:  S Friedman; E L Ford-Jones
Journal:  Paediatr Child Health       Date:  1999-01       Impact factor: 2.253

3.  Cytomegalovirus DNA detection on Guthrie cards in patients with neonatal cholestasis.

Authors:  B Fischler; P Rodensjö; A Nemeth; M Forsgren; I Lewensohn-Fuchs
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-03       Impact factor: 5.747

4.  Pp65 antigenemia, plasma real-time PCR and DBS test in symptomatic and asymptomatic cytomegalovirus congenitally infected newborns.

Authors:  Sandro Binda; Antonella Mammoliti; Valeria Primache; Patrizia Didò; Carlo Corbetta; Fabio Mosca; Lorenza Pugni; Anna Bossi; Cristian Ricci; Maria Barbi
Journal:  BMC Infect Dis       Date:  2010-02-11       Impact factor: 3.090

5.  Evaluation of different cytomegalovirus (CMV) DNA PCR protocols for analysis of dried blood spots from consecutive cases of neonates with congenital CMV infections.

Authors:  Oriane Soetens; Christelle Vauloup-Fellous; Ina Foulon; Pascal Dubreuil; Ben De Saeger; Liliane Grangeot-Keros; Anne Naessens
Journal:  J Clin Microbiol       Date:  2008-01-16       Impact factor: 5.948

6.  Virome characterisation from Guthrie cards in children who later developed acute lymphoblastic leukaemia.

Authors:  G Bogdanovic; C Pou; M Barrientos-Somarribas; A Bjerkner; E Honkaniemi; T Allander; B Andersson; B Gustafsson
Journal:  Br J Cancer       Date:  2016-08-23       Impact factor: 7.640

7.  Human herpes virus 6 or Epstein-Barr virus were not detected in Guthrie cards from children who later developed leukaemia.

Authors:  G Bogdanovic; A G Jernberg; P Priftakis; L Grillner; B Gustafsson
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.